IGC Pharma Overview
Valuation check: IGC's ROE is -128.59%, below the Healthcare sector average of -100.59%.
Get informed when a big investor buys or sells
+ Follow-128.59%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
IGC Pharma (IGC) currently reports a ROE of -128.59%. That is below the Healthcare sector average of -100.59%. Use the charts on this page to explore IGC Pharma's ROE history and peer comparisons.
IGC Pharma's ROE of -128.59% is lower than the Healthcare sector average of -100.59%. That is roughly 27.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but IGC Pharma's current -128.59% should be judged against Healthcare norms (sector average: -100.59%) and against IGC's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -128.59%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -100.59%. From there, open related valuation or income-statement pages for IGC Pharma, and consider following IGC for alerts when major investors trade the stock.
IGC Pharma is classified in the Healthcare sector. On ROE, it currently shows -128.59% versus a sector average near -100.59%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing IGC with unrelated industries.
